Tag: #biotech

Amgen discloses material cybersecurity incident after data exfiltration from third‑party cloud environments

Amgen disclosed a material cybersecurity incident in a July SEC filing, saying unauthorized activity in third‑party cloud environments led to exfiltration of proprietary and patient data.

$AMGN, #amgen, #cybersecurity, #biotech, #sec

Deramiocel improves arm function and cardiac measures in phase 3 trial as FDA advisory panel reviews Capricor's application

Phase 3 trial of deramiocel (CAP-1002) showed significant benefits on upper-limb function and cardiac measures; FDA advisory panel is reviewing the data.

$CAPR, #duchenne, #muscular-dystrophy, #biotech, #fda

Intellia’s one-time CRISPR therapy cuts hereditary angioedema attacks 87% in Phase 3; rolling FDA filing started

Phase 3 trial of Intellia's one-time in‑vivo CRISPR therapy lonvo‑z cut hereditary angioedema attacks 87%; company began rolling FDA filing.

$NTLA, #crispr, #geneediting, #biotech, #hereditaryangioedema, #intellia

Neurocrine to Buy Soleno for $2.9 Billion, Picks Up Prader‑Willi Drug VYKAT XR

Neurocrine will acquire Soleno for $2.9B to add VYKAT XR, the newly approved Prader‑Willi hyperphagia drug, aiming to expand its rare‑disease portfolio.

#biotech, #m&a, #raredisease